Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)

<p>Abstract</p> <p>Background</p> <p>The main hypothesis of this study is that oral heme iron polypeptide (HIP; Proferrin<sup>® </sup>ES) administration will more effectively augment iron stores in erythropoietic stimulatory agent (ESA)-treated peritoneal di...

Full description

Bibliographic Details
Main Authors: Isbel Nicole M, Campbell Scott B, Hawley Carmel M, Brown Fiona, Leary Diana, Noble Euan, Barraclough Katherine A, Mudge David W, van Eps Carolyn L, Sturtevant Joanna M, Johnson David W
Format: Article
Language:English
Published: BMC 2009-07-01
Series:BMC Nephrology
Online Access:http://www.biomedcentral.com/1471-2369/10/20